First AD

Second AD

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

David S. Siegel, MD, PhD 

OncLive News Network®

Pomalidomide and Carfilzomib in Refractory Multiple Myeloma

Treatment Approaches in Newly Diagnosed Multiple Myeloma

High-Risk Versus Low-Risk Multiple Myeloma

Multiple Myeloma: Considerations in Stem Cell Transplantation

Resistance to Multiple Myeloma Maintenance Therapy

Panobinostat in Relapsed/Refractory Multiple Myeloma

Role of Carfilzomib in Multiple Myeloma

Monoclonal Antibodies in Multiple Myeloma

Immunomodulatory Agents in Multiple Myeloma